Abstract：
The objective of this scoping review is to identify, map, and characterize the evidence for assessments that measure driving performance in people taking benzodiazepine receptor agonists.
Benzodiazepines and Z-drugs are widely prescribed for the treatment of anxiety disorders and insomnia even though they are not recommended as an initial treatment for these indications. Benzodiazepine and Z-drug use is associated with an elevated risk of traffic accidents, and guidance documents instruct patients to consult with their health care providers for instructions on how to safely operate a motor vehicle while consuming these medications. However, little is known about the assessments that measure driving performance regarding the extent and length of impairment from the consumption of the individual benzodiazepines and Z-drugs.
Eligible studies will include participants who are new, intermittent, or chronic users of benzodiazepines and Z-drugs. No exclusions will be applied regarding the health status of participants or whether their benzodiazepine and Z-drug use is for an approved indication as indicated by government agencies (eg, Health Canada) or practice guidelines. Studies that examine the consumption of a benzodiazepine and Z-drug in association with the operation of a motor vehicle (real or simulated) with direct or indirect objective or standard subjective measures or indicators of impairment while operating a motor vehicle will be considered.
Embase (Elsevier), MEDLINE (Ovid), and PsycINFO (EBSCO) will be searched as sources of published studies. Only studies published in English will be included, and there will be no limit on dates of publication. After screening the titles and abstracts of identified citations, two independent reviewers will retrieve potentially relevant full-text studies and extract data. Data will be presented in diagrammatic or tabular form accompanied by a narrative summary.
Benzodiazepines and Z-drugs are widely prescribed for the treatment of anxiety disorders and insomnia even though they are not recommended as an initial treatment for these indications. Benzodiazepine and Z-drug use is associated with an elevated risk of traffic accidents, and guidance documents instruct patients to consult with their health care providers for instructions on how to safely operate a motor vehicle while consuming these medications. However, little is known about the assessments that measure driving performance regarding the extent and length of impairment from the consumption of the individual benzodiazepines and Z-drugs.
Eligible studies will include participants who are new, intermittent, or chronic users of benzodiazepines and Z-drugs. No exclusions will be applied regarding the health status of participants or whether their benzodiazepine and Z-drug use is for an approved indication as indicated by government agencies (eg, Health Canada) or practice guidelines. Studies that examine the consumption of a benzodiazepine and Z-drug in association with the operation of a motor vehicle (real or simulated) with direct or indirect objective or standard subjective measures or indicators of impairment while operating a motor vehicle will be considered.
Embase (Elsevier), MEDLINE (Ovid), and PsycINFO (EBSCO) will be searched as sources of published studies. Only studies published in English will be included, and there will be no limit on dates of publication. After screening the titles and abstracts of identified citations, two independent reviewers will retrieve potentially relevant full-text studies and extract data. Data will be presented in diagrammatic or tabular form accompanied by a narrative summary.
摘要：
本次范围审查的目的是确定，地图，并表征评估服用苯二氮卓受体激动剂的人的驾驶表现的证据。
苯二氮卓类药物和Z类药物被广泛用于治疗焦虑症和失眠，尽管它们不被推荐作为这些适应症的初始治疗。苯二氮卓类药物和Z类药物的使用与交通事故的风险增加有关,和指导文件指示患者咨询他们的医疗保健提供者，以获取有关如何在服用这些药物时安全操作机动车辆的说明。然而,关于从单个苯二氮卓类药物和Z类药物的消耗中衡量驾驶表现的损害程度和长度的评估知之甚少.
符合条件的研究将包括新的参与者，间歇性,或长期使用苯二氮卓类药物和Z类药物。对于参与者的健康状况或其苯二氮卓类药物和Z-药物的使用是否为政府机构指示的批准适应症（例如，加拿大卫生部)或实践指南。将考虑在操作机动车辆时使用直接或间接的客观或标准的主观措施或损害指标来检查与机动车辆（真实或模拟）操作相关的苯二氮卓和Z-药物的消耗。
Embase(Elsevier),MEDLINE(Ovid),和PsycINFO（EBSCO）将作为已发表研究的来源进行搜索。只有以英文发表的研究才会包括在内，出版日期没有限制。筛选已确定引文的标题和摘要后，两名独立审稿人将检索潜在相关的全文研究并提取数据.数据将以图表或表格形式呈现，并附有叙述性摘要。
苯二氮卓类药物和Z类药物被广泛用于治疗焦虑症和失眠，尽管它们不被推荐作为这些适应症的初始治疗。苯二氮卓类药物和Z类药物的使用与交通事故的风险增加有关,和指导文件指示患者咨询他们的医疗保健提供者，以获取有关如何在服用这些药物时安全操作机动车辆的说明。然而,关于从单个苯二氮卓类药物和Z类药物的消耗中衡量驾驶表现的损害程度和长度的评估知之甚少.
符合条件的研究将包括新的参与者，间歇性,或长期使用苯二氮卓类药物和Z类药物。对于参与者的健康状况或其苯二氮卓类药物和Z-药物的使用是否为政府机构指示的批准适应症（例如，加拿大卫生部)或实践指南。将考虑在操作机动车辆时使用直接或间接的客观或标准的主观措施或损害指标来检查与机动车辆（真实或模拟）操作相关的苯二氮卓和Z-药物的消耗。
Embase(Elsevier),MEDLINE(Ovid),和PsycINFO（EBSCO）将作为已发表研究的来源进行搜索。只有以英文发表的研究才会包括在内，出版日期没有限制。筛选已确定引文的标题和摘要后，两名独立审稿人将检索潜在相关的全文研究并提取数据.数据将以图表或表格形式呈现，并附有叙述性摘要。
